Bergamasco B, Villardita C, Coppi R
III Neurologic Clinic, University of Turin, Italy.
Arch Gerontol Geriatr. 1992 Nov-Dec;15(3):279-86. doi: 10.1016/0167-4943(92)90063-a.
A randomized, multicentre study on idebenone vs. oxiracetam was carried out in order to evaluate the therapeutic efficacy of idebenone in subjects with senile cognitive decline. Seventy-nine patients were enrolled: 39 treated with idebenone 45 mg twice daily p.o. and 40 treated with oxiracetam 800 mg twice daily p.o. Idebenone proved to be more effective and was shown to be statistically significant in the following test: SCAG, Rey's 15 Words, Gottfries Rating Scale. The greater efficacy of idebenone was confirmed by the efficacy judgement given by the investigators. The tolerability of both treatments can be said to be most satisfactory: none of the patients left the study because of side-effects. No significant variations were observed in the vital signs.
为评估艾地苯醌对老年认知功能减退患者的治疗效果，开展了一项关于艾地苯醌与奥拉西坦对比的随机多中心研究。共纳入79例患者：39例接受艾地苯醌治疗，口服剂量为每日两次，每次45mg；40例接受奥拉西坦治疗，口服剂量为每日两次，每次800mg。在以下测试中，艾地苯醌被证明更有效且具有统计学意义：简易精神状态检查表（SCAG）、雷氏15词测验、戈特弗里德评定量表。研究者给出的疗效判断证实了艾地苯醌具有更强的疗效。两种治疗的耐受性均可说是非常令人满意：没有患者因副作用而退出研究。未观察到生命体征有明显变化。
